ReNerve

ASX Announcement

10 October 2025

ReNerve product range to feature at American Society for Surgery of the Hand (ASSH) event

ReNerve Limited (ASX, "**ReNerve**" or "the **Company**"), an Australian pioneering medical device company developing innovative products for peripheral nerve injury ("**PNI**") repair, is pleased to announce that its product portfolio will be the feature of an industry forum focused on nerve repair.

The American Society for Surgery of the Hand (ASSH) event in Vancouver reviews methods of nerve repair and will illustrate the use of the various ReNerve nerve repair products including its nerve cuff, nerve conduit and nerve guide matrix.

During ASSH, ReNerve will also be launching its complementary human tissue Empliq product ranges.

ReNerve is developing a portfolio of peripheral nerve repair and replacement products allowing surgeons to complete a wide range of nerve repairs, from the less complicated, such as coopted severed nerves, through to the most complex of procedures including the replacement of damaged nerves. ReNerve's unique NervAlign® Nerve Cuff has been successfully used in a variety of surgical settings and has enjoyed strong endorsement from leading surgeons. It is expected to be joined on the market shortly by the first of ReNerve's nerve conduit products.

The Company is also developing a nerve guide matrix as a room temperature stored 'ready-to-go' alternative to nerve grafts or harvested nerve replacement. This will give ReNerve a unique position in the market with a complete portfolio for all aspects of peripheral nerve repair, with products that are functional and convenient, all stored at room temperature to make them practical for logistics and use.

"The event is designed to show attendees the various techniques for repairing and replacing injured peripheral nerves. ReNerve has the competitive advantage that it is developing a comprehensive range of nerve repair products to enable surgeons to approach any and all nerve repairs with options, to the benefit of patients, and this industry event will highlight the benefits of our range," **said ReNerve CEO Dr Julian Chick.**

ReNerve is progressing the commercialisation of deep dermal and amniotic tissue-based product ranges under a strategic partnership with Berkeley Biologics LLC announced on 2 June 2025. ReNerve is leveraging its eCOO technology, already proven through its Nervalign® Nerve Cuff, to develop and bring to market a range of nerve conduit products. The global market for peripheral nerve repair is estimated to be around USD$1.6Bn and growing at 17+%. The global dermal and amniotic tissue market is estimated to be worth around USD$2.7 billion in 2024 and growing at around 12% CAGR[1], with these products used in a range of applications.

- ENDS -

[1] MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product --** A unique deep dermal product used in reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.96 billion in 2024 and is projected to reach $6.2 billion by 2031.[2]

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

[2] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)